MEDMEDConsumer Non-Cyclicals · Personal Services

MED Stock Forecast: Medifast, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$12
−1.92% on the day

The median 12-month analyst price target for Medifast, Inc. is $12. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 47 of 100 as at 21 Nov 2026 — in the lower half.

Market cap
$134.0M
Ticker Nerd rank
47/ 100
Median analyst target
$12
Analysts covering
1
Revenue$76.4M−27.6% y/y
Operating income−$4.3M
Net income−$3.1M
Free cash flow$728K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−9.4%
1M
−2.6%
YTD
+10.0%
1Y
+12.8%
From 52W high
−12.1%
From 52W low
+24.3%
$9
$13
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Medifast, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
47/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Accruals
95
Revisions
85
Momentum
48
Volatility
41
Quality
33
Issuance
31
Growth
25
Value
5

Accruals (95): Reported profit is backed by cash, and the company is not expanding recklessly.

Value (5): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

MED stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on MED, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$9$10$11$12$13Jan 26Apr 26Jul 26Oct 26MEDHigh $12Median $12Low $12

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0
Buy
1
Hold
0
Sell
$12
Low
$12
Median
$12
High
Recent analyst actionsNewest first
DateFirmActionRatingTarget
19 Feb 2026Stephens & Co.MaintainsEqual-Weight$15 → $12
19 Feb 2025DA DavidsonMaintainsNeutral—
5 Nov 2024DA DavidsonUpgradeNeutral—
22 July 2024DA DavidsonMaintainsUnderperform—
5 June 2024DA DavidsonDowngradeUnderperform—
30 Apr 2024DA DavidsonMaintainsNeutral—
21 Feb 2024DA DavidsonMaintainsNeutral—
13 Oct 2023Stephens & Co.InitiatesEqual-Weight—
8 Aug 2023DA DavidsonMaintainsNeutral—
31 July 2023DA DavidsonMaintainsNeutral—
2 May 2023DA DavidsonMaintainsNeutral—
22 Feb 2023DA DavidsonMaintainsNeutral—
4 Nov 2022DA DavidsonDowngradeNeutral—
4 Aug 2022DA DavidsonMaintainsBuy—
4 Aug 2022JefferiesDowngradeHold—
2 June 2022DA DavidsonMaintainsBuy—
24 Feb 2022DA DavidsonMaintainsBuy—
8 Nov 2021DA DavidsonMaintainsBuy—
5 May 2021DA DavidsonMaintainsBuy—
26 Feb 2021DA DavidsonMaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for MED.

Market Radar

This page is one stock. Monday covers all of them.

MED appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

MED vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 20 Nov 2026, Medifast, Inc. returned +12.8% against +6.9% for the S&P 500, dividends included.

MED vs S&P 500, last 12 monthsTotal return, rebased to 100
90100110120130Jan 26Apr 26Jul 26Oct 26MEDS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

MED analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
1
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
0.4×

Cheaper than 81% of US stocks

Price / book
0.7×

Cheaper than 81% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
69.9%

Higher than 82% of US stocks

Operating margin
−11.6%

Higher than 25% of US stocks

Net margin
—
Returns & dividend
Return on equity
−20.7%

Higher than 32% of US stocks

Return on assets
−8.6%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Medifast, Inc. has a market value of $134.0M.

  • Revenue in the twelve months to 30 June 2026: $316.9M. The latest quarter shrank 27.6% year on year.

  • Net income over the same four quarters: −$25.6M, a −8.1% net margin.

  • Diluted earnings per share, trailing twelve months: −$2.33.

  • Free cash flow in the twelve months to 30 June 2026: $4.0M.

  • Medifast, Inc. spent $813K on share buybacks and $170K on dividends in the twelve months to 30 June 2026.

  • Shares outstanding: 11.2M.

  • Medifast, Inc. employs 380 people — $834K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

MED and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelPersonal Services
CompanyMarket capTKN rank
MEDMedifast, Inc.$134.0M47
EJHE-Home Household Service Holdings Ltd.$83.0M20
RGSRegis Corp.$49.1M43
CSVCarriage Services, Inc.$457.3M39
BFAMBright Horizons Family Solutions, Inc.$2.4B43
PLBYPlayboy, Inc.*$129.8M46
DLTHDuluth Holdings, Inc.*$139.6M98

* Nearest Consumer Cyclical names by size — few personal services companies of this scale trade in the US universe.

Take a look at MED’s peer groups, ranked by the model: consumer staples stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Medifast, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about MED

What is the MED stock price forecast for 2026-2027?

The median 12-month analyst price target for Medifast, Inc. is $12. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is MED stock a buy right now?

Of the 1 analyst covering Medifast, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Medifast, Inc. 47 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank MED?

As at 21 Nov 2026, Medifast, Inc. ranks 47 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Accruals (95 of 100).

Will MED stock go up?

No one can know that. What the data says: the median 12-month target from 1 analyst is $12, and Ticker Nerd's factor model ranks Medifast, Inc. 47 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the MED stock forecast for 2030?

No analyst covering Medifast, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for MED are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $12 to $12 over the next 12 months.

How has MED stock performed over the past year?

Medifast, Inc. returned +12.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Medifast, Inc. do?

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines.

Company

About Medifast, Inc.

Medifast Inc. is a health and wellness company focused on habit-based, coach-guided lifestyle solutions for weight management and metabolic health. The company’s core offering centers on the OPTAVIA brand, which combines structured nutrition products, meal replacements, and coaching support to help customers build healthier daily routines. Medifast Inc. sells a range of products including shakes, bars, soups, cereals, and other nutrition items designed for convenience and consistency within its program model. Its business serves individuals seeking weight loss and long-term healthy living support, while also relying on a network of independent coaches and digital ordering channels to deliver its services. Headquartered in Baltimore, Maryland, Medifast Inc. plays a specialized role in the broader wellness market by integrating products, guidance, and behavior-change support into a single customer experience.

CEO Mr. Nicholas M. Johnson · 380 employees · United States · https://medifastinc.com